NCT07171203 2026-03-25
Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor
University of California, San Diego
Phase 1 Recruiting
Clinical Trials
50 trialsNCT01046487 2026-03-13
PALANGI3
Centre Oscar Lambret
Phase 1 Completed
NCT05493215 2026-02-17
Imatinib TDM in GIST
University of Kentucky
Phase 2 Recruiting
NCT05152472 2026-01-08
ATEZOGIST
Centre Leon Berard
Phase 2 Recruiting
NCT01991379 2025-12-04
MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
NCT05385549 2025-08-08
5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk
Asan Medical Center
Phase 2 Recruiting
NCT02413736 2025-03-12
Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST
Helsinki University Central Hospital
Phase 3 Active not recruiting
NCT06038552 2025-02-26
Comparison of Clinical Efficacy of Liver Resection, RFA, TACE, and Drug Therapy in Patients with GIST LM
First Affiliated Hospital, Sun Yat-Sen University
Completed
NCT06628739 2024-10-08
Correlation Between Imatinib Trough Concentration and Efficacy in Advanced GIST Patients with Different Genotypes
First Affiliated Hospital, Sun Yat-Sen University
Completed
NCT01738139 2024-03-21
Ipilimumab and Imatinib Mesylate in Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02260505 2024-01-05
ImadGist
Centre Leon Berard
Phase 3 Completed
NCT01541709 2024-01-02
Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI
Asan Medical Center
Phase 2 Unknown
NCT04006769 2023-10-18
Entacapone Combination With Imatinib for Treatment of GIST
Xiangya Hospital of Central South University
Phase EARLY_PHASE1 Completed
NCT05009927 2023-09-01
Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)
Centre Leon Berard
Phase 2 Recruiting
NCT05970900 2023-08-01
PIRKER
Fujian Medical University Union Hospital
Phase 3 Not yet recruiting
NCT00764595 2023-07-21
GISTs
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Phase 2 Completed
NCT05895942 2023-06-09
EMMBKM
Xijing Hospital
Unknown
NCT04138381 2023-03-27
SeliGIST
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2 Unknown
NCT02712112 2023-01-04
A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs
Asan Medical Center
Phase 2 Completed
NCT03609424 2023-01-03
PDR001 Plus Imatinib for Metastatic or Unresectable GIST
Asan Medical Center
Phase 1/2 Completed
NCT04933669 2021-10-12
ZJGIST-01
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT02257541 2020-03-30
BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT01151852 2020-01-14
Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT
Asan Medical Center
Phase 3 Completed
NCT00278876 2020-01-07
Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation
Asan Medical Center
Phase 2 Completed
NCT03862768 2019-03-05
Role of Surgery in Patients With Focally Progressive Gastrointestinal Stromal Tumors (GISTs) After Imatinib Treatment
Shanghai Zhongshan Hospital
Phase NA Unknown
NCT00401024 2018-06-28
Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT00010049 2018-06-27
Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT01137916 2017-05-03
Study to Evaluate Imatinib in Desmoid Tumors
Heidelberg University
Phase 2 Completed
NCT00585221 2017-02-10
Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients
University of Utah
Phase 2 Terminated
NCT00287846 2016-08-30
Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis
UNICANCER
Phase 1/2 Completed
NCT02576080 2015-10-15
GIGIST
Assistance Publique Hopitaux De Marseille
Phase 3 Unknown
NCT00387933 2015-10-14
Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma
Duke University
Phase 1 Completed
NCT00293124 2015-08-13
Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors
Central European Cooperative Oncology Group
Phase 3 Completed
NCT02268435 2015-08-04
Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors
Asan Medical Center
Phase 1 Withdrawn
NCT01267695 2015-02-03
Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
Peking University
Phase 2 Completed
NCT01031628 2013-09-09
Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients
Sarcoma Alliance for Research through Collaboration
Phase 3 Terminated
NCT00354068 2013-03-28
Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma
Duke University
Phase 1 Completed
NCT00615927 2013-03-15
Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)
Duke University
Phase 2 Completed
NCT00613132 2013-02-20
Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG
Duke University
Phase 1 Completed
NCT00354913 2013-01-18
Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma
Duke University
Phase 2 Completed
NCT01175109 2012-12-27
Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma
University of Virginia
Phase 1 Unknown
NCT00613054 2012-12-05
Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma
Duke University
Phase 1 Completed
NCT00243191 2012-03-29
Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans
Sarcoma Alliance for Research through Collaboration
Phase 2 Completed
NCT00112632 2012-03-08
Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
Technical University of Munich
Phase 2 Completed
NCT00116935 2011-12-30
Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)
Scandinavian Sarcoma Group
Phase 3 Completed
NCT00573404 2011-11-16
Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors
Vanderbilt-Ingram Cancer Center
Phase 1 Terminated
NCT00500188 2011-08-08
Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00122473 2011-07-29
Imatinib in Dermatofibrosarcoma Protuberans (DFSP)
Dermatologic Cooperative Oncology Group
Phase 1/2 Completed
NCT00062205 2010-02-09
Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor
City of Hope Medical Center
Phase 2 Completed
NCT00290485 2006-04-07
Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)
Maisonneuve-Rosemont Hospital
Phase 2 Unknown